Matthew Matasar, MD

Dr Matthew Matasar | Image Credit: Rutgers Cancer Institute

Matthew Matasar, MD, is the chief of blood disorders at Rutgers Cancer Institute.

Articles by Matthew Matasar, MD

EHA 2025 Congress Recap | Image Credit: Venngage

Global Hematology Experts Reflect on Key Takeaways From the EHA 2025 Congress

ByBrooke McCormick,Marina Kremyanskaya, MD, PhD,Lorna Warwick,Xavier Leleu, MD, PhD,Ashley Yocum, PhD,Matthew Matasar, MD,Adela Perolla, MD, PhD

June 16th 2025

At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.

Phase 3 POLARGO Trial Shows Survival Benefit of Polatuzumab-Based Regimen in R/R DLBCL: Matthew Matasar, MD

ByBrooke McCormick,Matthew Matasar, MD

June 14th 2025

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to Matthew Matasar, MD, of Rutgers Cancer institute.

Matthew Matasar, MD

Articles by Matthew Matasar, MD

Global Hematology Experts Reflect on Key Takeaways From the EHA 2025 Congress

Phase 3 POLARGO Trial Shows Survival Benefit of Polatuzumab-Based Regimen in R/R DLBCL: Matthew Matasar, MD

Latest Updated Articles

Trending on AJMC

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC

New Biomarkers, Drug Targets Identified for Colorectal Cancer

Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability

Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations